Theranostics

Theranostics, or "therapy" + "diagnostics", is simply finding and treating disease at the same time, often using the same medicine to spot the disease and then target it for treatment. This medical approach is precise, personalized, and targeted—treating what can be seen.  

At East River Medical Imaging's Molecular Imaging & Theranostics Suite, patients with advanced, metastatic prostate cancer can receive molecular targeted radiation therapy called PLUVICTO®, or lutetitum Lu-177 vipivotide tetraxetan. This FDA approved cancer treatment uses a radiopharmaceutical drug to seek out and attach to cancer cells, deliver radiation directly to them, and kill cancer cells while limiting damage to healthy tissue. 

You may be eligible for PLUVICTO® therapy if the following applies to you: 

• You are an adult (> 18 years old) with metastatic castration-resistant prostate cancer (mCRPC). 

• You have had a prostate-specific membrane antigen (PSMA)-positive PET scan. 

• You have previously had at least 1 androgen (hormone) therapy. 

• You have or have not undergone chemotherapy. 

Learn more about PLUVICTO® treatment here and if it's right for you. 

East River Medical Imaging has a long history of diagnostic imaging excellence, including early introduction of advanced MRI and PSMA PET/CT exams for prostate cancer in the outpatient setting. East River Imaging has continued its leadership position with the installation of the first GE StarGuide SPECT/CT scanner in the tri-state area.

This state-of-the-art machine provides more precise images offering patients and our doctors a clear picture of disease spread to tailor each patient's therapy. Many PLUVICTO® treatment centers are unable to provide regular imaging to clearly visualize the progress and success of therapy during treatment. At East River Medical Imaging, you can get a glimpse after every appointment. 

Douglas DeCorato, MD, FACR
Chief of Molecular Imaging and Theranostics
East River Medical Imaging, PC

Dr. Douglas DeCorato is a nationally recognized radiologist, partner, and Radiation Safety Officer for East River’s Manhattan offices. He earned his medical degree from SUNY Downstate Medical Center in 1990, completed his internship at Staten Island University Hospital, and finished his radiology residency at St. Luke’s–Roosevelt Hospital Center in 1995. He went on to complete a prestigious Body MRI fellowship at NYU in 1996.

Dr. DeCorato served as an attending radiologist at Beth Israel Medical Center before joining Memorial Sloan Kettering Cancer Center as Assistant Professor of Radiology. Since 2000, he has been a driving force at East River Medical Imaging, where he now serves as Chief of Molecular Imaging and Theranostics.

A Fellow of the American College of Radiology (FACR), Dr. DeCorato continues to advance the field through innovation in molecular imaging and targeted radionuclide therapy, leading both clinical & research related theranostics. In 2025, he achieved Authorized User status and completed a specialized theranostics preceptorship at BAMF Health, further strengthening his expertise in cutting-edge precision oncology.

If you believe you qualify for PLUVICTO® therapy, discuss your eligibility with your doctor (urologist, medical oncologist, etc.), and book an initial consultation to discuss treatment with Dr. DeCorato. Your doctor can also book directly with us by sending us a referral for your treatment.

For providers wishing to refer their patients for PLUVICTO® therapy, contact us at theranostics@eastriverimaging.com or submit a referral above.